Board of Directors

Predictive Biosciences' Board of Directors comprises a team of leading investors, scientists, and industry executives.

Michael A. Greeley

General Partner, Flybridge Capital Partners

Michael founded Flybridge Capital Partners and is a General Partner focusing on information technology, healthcare and medical technology investments. He currently represents Flybridge Capital Partners on the boards of BlueTarp, MicroCHIPS, Predictive Biosciences, ProteinForest and VidSys and led the firm's investment in T2 Biosystems and Magen BioSciences.

Prior to founding Flybridge Capital Partners, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, Michael served for over five years as Senior Vice President and Founding Partner of GCC Investments, a successful $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston.

In previous positions, Michael has served on the Boards of a number of public and private companies including Global TeleSystems Group (NASDAQ: GTSG), El Sitio International (NASDAQ: LCTO), MotherNature.com (NASDAQ: MTHR), Crescent Communications (acquired by Clear Channel), Fleetcor Technologies and American Capital Access.

Michael currently serves as the President of the New England Venture Capital Association, is a member of the Executive Business Advisory Council for Mass General Hospital for Children, and is a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary.

Michael received a BA with honors in Chemistry from Williams College and an MBA fromHarvard Business School.

M. James Barrett, Ph.D.

General Partner, New Enterprise Associates (NEA)

Dr. M. James Barrett joined New Enterprise Associates (NEA) in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. In addition to Predictive, he currently resides on the board of directors for Cardioxyl Pharmaceuticals, GlycoMimetics, Inc., Inhibitex, Inc. (NASDAQ: INHX), Nucleonics, Inc., Peptimmune, Inc., Proteostasis Therapeutics, Inc., Ruxton Pharmaceuticals, Sensors for Medicine and Science,  Inc., Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. 

Prior to joining NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001), where he remains Chairman.  Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983).  Prior to 1982, he worked in various divisions of SmithKline.

Jim received his Ph.D. in Biochemistry at the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.

Kim D. Blickenstaff

President and Chief Executive Officer, Tandem Diabetes Care, Inc.

Mr. Blickenstaff has more than 30 years of healthcare experience in finance, marketing management, sales and strategic planning. Since 2007, Kim has served as President and Chief Executive Officer of Tandem Diabetes Care, Inc., a San-Diego based medical device company developing insulin pumps for diabetics. Prior to joining Tandem, he was Chairman, Chief Executive Officer and co-founder of medical diagnostic company Biosite Incorporated, which pioneered a novel blood test to diagnose and monitor patients with heart failure. Biosite was acquired by Inverness Medical Innovations for $1.8 billion in June 2007. Before founding Biosite, Kim held various management positions with Hybritech Incorporated and Baxter Healthcare.

Kim has been active in the medical device and diagnostics industry serving on the board of directors for innovative, young healthcare companies such as SenoRx and Medivation Incorporated. He holds a Masters of Business Administration from Loyola University Chicago's Graduate School of Business.

Peter Klemm, Ph.D.

President and Chief Executive Officer

Dr. Peter Klemm leads Predictive Biosciences overall to achieve key corporate milestones. He is the former Chief Executive Officer of GeneOhm Sciences, a molecular diagnostics company pioneering the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs). Dr. Klemm joined GeneOhm (founded in 2001) in May 2002 as CEO and oversaw the company’s acquisition by Becton Dickinson in February 2006 for $230 million. GeneOhm investors included Domain Associates, CHL Medical Partners, Kaiser Permanente Ventures, Partners HealthCare, Questmark Partners, Wasatch Advisors, and others.

Dr. Klemm was previously Chief Executive Officer of JOMED Inc., a Swiss-based company that develops and manufactures products for interventional cardiology, radiology and minimally invasive vascular surgery. Following JOMED's successful IPO in April 2000 and with the acquisition of Endosonics Inc, Dr. Klemm moved to the United States to integrate the companies and was appointed Chief Executive Officer of JOMED Inc. Prior to joining JOMED, he was SVP of R&D at Gruenenthal GmbH, a European pharmaceutical company, where Dr. Klemm established state of the art drug discovery technologies and central analgesic therapies. Prior to Gruenenthal, Dr. Klemm joined Aventis as Senior Scientist within the cardiovascular drug discovery unit and spent one year as a post doctoral fellow at the William Harvey Research Institute in London with Sir John Vane.

Robert S. Langer, Sc.D.

Institute Professor, Massachusetts Institute of Technology

Dr. Langer is one of 13 Institute Professors (the highest rank awarded to a faculty member) at the Massachusetts Institute of Technology (MIT).

Bob has written more than 900 articles and has over 550 issued or pending patents worldwide (one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the U.S.). He has received nearly 150 major awards, including the Gairdner Foundation International Award (68 recipients have subsequently received a Nobel Prize), the Lemelson-MIT Prize (the world's largest prize for invention), and the Charles Stark Draper Prize (the world's most prestigious engineering prize, from the National Academy of Engineering). In 1989, Bob was elected to the Institute of Medicine and the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. Forbes Magazine (1999) and Bio World (1990) have named him as one of the 25 most important individuals in biotechnology in the world.

Bob has received honorary doctorates from multiple institutions. He received a Bachelor's Degree from Cornell University in 1970 and his Sc.D. from MIT in 1974, both in chemical engineering.

Jay Moorin

General Partner, ProQuest Investments

Mr. Moorin is a founding General Partner at ProQuest. He is a healthcare executive with senior management experience in biotech, investment banking and pharmaceutical industry. Prior to founding ProQuest, Mr. Moorin served as CEO of Magainin Pharmaceuticals (now Genaera Corp.). Previously, he was Managing Director of Health Care Banking at Bear, Stearns & Co. Mr. Moorin has also held various positions in strategy and general management at E.R. Squibb & Sons Pharmaceuticals. He has served on the Board of Directors of ACMI, Epic Therapeutics, Gloucester Pharmaceuticals, Guava Technologies, Mersana Therapeutics, Novacea (now Transcept) and Pharmion. Currently, Mr. Moorin serves on the Board of Directors of Acurian, Aires Pharmaceuticals, Eagle Pharmaceutical, MethylGene and Predictive Biosciences.

Mr. Moorin holds the position of Adjunct Senior Fellow of the Leonard Davis Institute of Health Economics at the University of Pennsylvania. He received a B.A. in economics with distinction from the University of Michigan.

Marsha A. Moses, Ph.D. (Co-Founder)

Julia Dyckman Andrus Professor, Harvard Medical School and Director, Vascular Biology Program, Children's Hospital Boston

Dr. Marsha Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Children's Hospital Boston. She also leads the Urinary Proteomics Initiative first established in her laboratory, the focus of which is the identification and validation of non-invasive biomarkers for human cancers.

Marsha is an internationally recognized expert in the regulation of angiogenesis and leads a research group that conducts both basic and translational research. She and her group have discovered many different angiogenesis inhibitors, several of which are being developed for clinical use. Her research provided some of the earliest proof linking matrix metalloproteinases to successful angiogenesis.

Marsha has authored over 100 peer-reviewed publications, including articles in Science, Cell, the Journal of Biological Chemistry and The New England Journal of Medicine. She has presented over 100 lectures to national and international audiences. Dr. Moses holds approximately 70 patents, both issued and pending, in the United States, Canada, Europe and Asia. Her awards and honors include the Cancer Research Foundation Award, the American Cancer Society Research Award, and the Center for Excellence in Women's Health Research Award from Harvard Medical School. In 2008, she was elected to the prestigious Institute of Medicine of the National Academy of Sciences, one of the highest honors in the fields of health and medicine.

Marsha earned her Ph.D. from Boston University.

Bijan Salehizadeh, M.D.

General Partner, Highland Capital Partners

Bijan partners with entrepreneurs and management of medical devices and biotechnology healthcare companies. He represents Highland on the board of Hyperion Therapeutics, OpGen and Predictive Biosciences, and is or has been actively involved in Highland's investments in BAROnova and Conor Medsystems (IPO; acquired by Johnson & Johnson). He is based in Highland Capital’s Menlo Park office.

Prior to joining Highland, Bijan spent several years in marketing and strategic planning at Medtronic Vascular, a world leader in medical technology. Before Medtronic, Bijan was the Director of Business Development for HealthCentral, a venture-backed start-up that went public in 1999. During his medical training, Bijan conducted research in minimally invasive heart valves and left ventricular assist devices, and his work was published in several peer-reviewed scientific journals. He also served as a researcher at the National Heart, Lung, and Blood Institute where he investigated coronary artery disease. Bijan earned his A.B. in Molecular Biology from Princeton University, an M.S. in Health Policy and M.D. from Columbia University, and his MBA from Harvard Business School.